CONRAY (iothalamate meglumine) by Guerbet is clinical pharmacology following intravascular injection, conray is rapidly transported through the circulatory system to the kidneys and is excreted unchanged in the urine by glomerular filtration. First approved in 1962.
Drug data last refreshed 3h ago · AI intelligence enriched 2w ago
CONRAY (iothalamate meglumine) is an iodinated contrast medium administered by intravascular injection for diagnostic imaging procedures. It works by rapid distribution through the circulatory system and excretion via glomerular filtration, enabling visualization of vascular and organ structures during angiography, CT scanning, and other radiographic procedures. The drug does not accumulate in normal brain tissue due to the blood-brain barrier, making it useful for contrast-enhanced neuroimaging.
As a legacy product approaching loss of exclusivity with moderate competitive pressure (30), the brand team is likely focused on cost management and market stabilization rather than growth initiatives.
CLINICAL PHARMACOLOGY Following intravascular injection, Conray is rapidly transported through the circulatory system to the kidneys and is excreted unchanged in the urine by glomerular filtration. The pharmacokinetics of intravascularly administered radiopaque contrast media are usually best…
Worked on CONRAY at Guerbet? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Careers linked to CONRAY offer limited growth trajectory given the product's LOE-approaching status and zero linked job openings. Professionals joining this brand would focus on defending market share, managing costs, and optimizing operational efficiency rather than driving innovation or expansion.